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Several possible tumour markers from the blood of patients with
small cell lung cancer (SCLC) have been described (Ferrigno and
Buccheri, 1995). The search for new ones continues in the hope 
of finding a marker which alone or in combination with other
markers could be helpful in prognosis-estimation, staging or moni-
toring of treatment. Chromogranin A (CgA) is well described as a
histochemical marker in SCLC (Rosa and Gerdes, 1994) but few
results regarding blood values of CgA from patients with SCLC
have been published (Sobol et al, 1986; Johnson et al, 1993).
Chromogranin A is a 49 kDa glycoprotein, reported for the first
time 30 years ago (Banks and Helle, 1965; Blaschko et al, 1967).
The primary structure consists of 439 amino acids (Konecki et al,
1987); and its gene is located on chromosome 14 (Murray et al,
1987). It is found in the neurosecretory granules of normal and
malignant neuroendocrine cells. CgA is released into the circula-
tion via exocytosis from neuroendocrine storage vesicles. The role
of CgA is not known precisely, but possible functions include
intracellular regulation of the formation of granules, regulation of
hormone secretion and function as a prohormone (Helle and
Angeletti, 1994; Hendy et al, 1995; Iacangelo and Eiden, 1995).
The aim of this study was to evaluate the value of plasma CgA
as a tumour marker in SCLC.
MATERIALS AND METHODS
Plasma samples were obtained after informed consent from 150
consecutive patients referred to the four hospitals participating in
the ‘Copenhagen Lung Cancer Study Group’ (Hirsch et al, 1994),
in the period April 1989 to January 1991. All patients had no prior
cancer and histologically confirmed SCLC except for 15 patients
from whom only cytological material was available. Before treat-
ment, the patients were classified as having limited or extensive
disease (LD/ED) on the basis of clinical examination, chest X-ray,
bone-marrow aspiration and biopsy from the iliac crest (unilateral:
ten patients; bilateral: 130 patients; not done: ten patients), and
ultrasound of the liver with biopsy, if possible, of suspect regions.
LD was defined as disease confined to one hemithorax excluding
proven malignant pleural effusion and chest wall metastases.
Ipsilateral supraclavicular lymph nodes were included in the
criteria of LD. Performance status (PS) was scored according to
the WHO system. Various biochemical tests, including complete
blood counts, plasma sodium, LDH, aspartate aminotransferase
(AST) and alkaline phosphatase (AP) were done. The pretreatment
characteristics for the patients are shown in Table 1. All samples
including plasma for CgA analysis were collected before the
initiation of chemotherapy. Patients were treated according to
treatment protocols including combinations of platin analogues,
podophyllotoxin derivatives, alkylating agents and vinca alkaloids
(Hirsch et al, 1994). None of the protocols included either surgery
or radiotherapy. Follow-up time for seven (8%) long time
survivors was for a minimum of 5 years. Control subjects were
28 healthy persons.
Blood samples were collected into tubes containing 3.9 mmol
ethylene-diaminetetraacetate (EDTA) per ml of blood and kept
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Table 1 Pretreatment characteristics in 150 patients with SCLC
LD ED LD + ED
Number of patients (%) 75 (50%) 75 (50%) 150 (100%)
Number of males (%) 45 (30%) 47 (31%) 92 (61%)
Median years of age (range) 65 (35–75) 62 (44–79) 63 (35–79)cool. After centrifugation, plasma was stored at –80°C until
assayed. Quantification of CgA in plasma was performed in dupli-
cate by an enzyme-linked immunosorbent assay (Chromogranin A
ELISA kits, code No. K 025, were kindly provided by Dako A/S,
Glostrup, Denmark). Plasma samples from the patients were
incubated simultaneously with peroxidase-conjugated anti-CgA
in microtitre plates (96 wells) coated with anti-CgA. Polyclonal
antibodies raised against a C-terminal fragment of CgA were used
in the assay.
Statistical analysis
Difference between values were tested for statistical significance
by Mann–Whitney test, as the values were not normally distrib-
uted. Lifetable probabilities of overall survival were performed by
the Kaplan–Meier method (Kaplan and Meier, 1958), and differ-
ences in survival between subgroups of patients were compared
with the log-rank test (Mantel, 1996) plus the test for trend if there
was a natural ordering of categories on the factor (Tarone, 1975).
Overall length of survival was measured from the day
chemotherapy was initiated. A P-value < 0.05 was considered
significant. The prognostic impact of the following pretreatment
variables was investigated by the use of Cox’s proportional
hazards multivariable regression model (Cox, 1972): sex, age,
stage of disease, PS, LDH, sodium, AST and AP. Together
with these variables, which have all previously been shown to be
prognostic factors, CgA was included. All variables were divided
into clinically meaningful groups (Table 2). All variables were
included in the initial model and excluded step-wise based on the
partial likelihood ratio test statistic.
Log minus log survival plots were made to check for pro-
portionality between death hazards. Finally, an algorithm for
prognostic categorization was created based on the regression
coefficients in the final model.
The statistical procedures were done on a PC using the
SPSS/7.0 (SPSS Inc., Chicago, IL, USA) software and the BMDP
statistical software (UC Press, Berkeley, CA, USA).
RESULTS
Median CgA-value from the healthy persons was 0.76 nmol l–1
(range 0.47–1.10). Values above the 97.5th percentile – 
1.10 nmol l–1 – were considered to be abnormally high/positive. The
CgA values for the 150 patients were as follows: median 0.89 nmol
l–1 (range and inter-quartile range: 0.25–9.08 and 0.59–1.39) and
37% had positive values. Patients with LD had a median CgA-value
of 0.85 nmol l–1 (range and inter-quartile range: 0.30–6.34 and
0.59–1.1) and with ED had a median CgA-value of 0.97 nmol l–1
(range and inter-quartile range: 0.25–9.08 and 0.59–1.73). Patients
with SCLC had significantly higher CgA than the control group 
(P = 0.049). For patients with LD, 27% had elevated values,
whereas 48% of patients with ED had elevated values. The con-
centrations in ED were significantly higher than in LD
(P = 0.039) and the group of healthy persons (P = 0.017). The
results are shown in Table 3. The CgA values were not related to
specific patterns or number of metastases.
Patients with positive pretreatment CgA values lived signifi-
cantly shorter (P = 0.001) compared to patients with normal CgA
values (Figure 1). The median survival and 95% confidence
interval (CI) for patients with increased pretreatment CgA is 196
days (40–352) and 342 days (288–396) for patients with normal
CgA values.
In order to study the influence of CgA beyond the first 30 days
from the start of treatment (i.e. beyond the period of early death)
another survival analysis was performed (Figure 2). There 
were 28 early deaths: progressive SCLC = 15, toxic death = six,
‘unknown’ = four and cardiovascular incidents = three.
Pretreatment CgA maintains its negative impact on survival after
the first 30 days (P = 0.03).
In order to evaluate the prognostic influence of CgA compared
to other known prognostic factors, a multivariate regression
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Table 2 Median duration of survival: influence of nine pretreatment clinical features
Variable Scorea No. of patients Median survival Pb TTc
examined (weeks)
Sex: male vs female 0,1 92 58 36 48 0.0050 –
Age (Y): Y ≤ 60 vs 60 < Y ≤ 70 vs Y > 70 0,1,2 62 79 9 48 41 21 0.0005 0.1227
Disease stage: limited vs extensive 0,1 75 75 55 35 0.0010 –
Performance status: 0–1 vs 2 vs 3–4 0,1,2 117 22 11 46 29 21 0.0013 0.0005
CgA: ≤ 1.1 vs > 1.1 nmol l–1 0,1 94 56 49 28 0.0014 –
Na: < 136 vs ³ 136 nmol l–1 1,0 40 102 31 45 0.0280 –
AST: ≤ 40 vs > 40 U l–1 0,1 122 23 46 20 0.0029 –
LDH: ≤ 450 vs 451–900 vs > 900 U l–1 0,1,2 73 33 38 59 35 32 0.0012 0.0003
AP: ≤ 275 vs 276–550 vs > 550 U/l–1 0,1,2 92 31 20 46 38 27 0.0049 0.0014
ascore used in Cox analysis (Table 4); blog rank; cTT: test for trend (log-rank).
Table 3 Pretreatment chromogranin A values in nmol l–1
n Median Range 2p Pct.elevateda
LD 75 0.85 0.30–6.34 27%
0.039
ED 75 0.97 0.25–9.08 48%
aCut-off: 1.10 nmol l–1.
Table 4 Prognostic factors in SCLC based on Cox regression analysis of
144 patients
Variable Coefficient SE P RR 95% CI
Performance status 0.4225 0.1463 0.0039 1.53 (1.14–2.04)
Disease stage 0.4553 0.1844 0.0135 1.58 (1.09–2.28)
Chromogranin A 0.4009 0.1851 0.0303 1.49 (1.03–2.16)
LDH 0.2525 0.1050 0.0162 1.29 (1.04–1.59)analysis was performed. Results of univariate analyses are summa-
rized in Table 2, which also shows the categorization (scoring) of
the variables. The final Cox model is shown in Table 4. No signifi-
cant interaction between the influences of P-CgA, PS, stage or
S-LDH was found. The prognostic information of these four vari-
ables could be combined into a prognostic index such as PI = 0.40
´ ZCgA + 0.42 ´ ZPS + 0.46 ´ Zstage + 0.25 ´ ZLDH but we chose the
approximation PI = ZCgA + ZPS + Zstage + 0.5 ´ ZLDH, because it is
much more handy in clinical practice. The resulting 11 prognostic
strata were changed into three prognostic categories: good (PI =
0–0.5), intermediate (PI = 1.0–1.5) and poor (PI = 2.0–5.0)
(Figure 3.).
DISCUSSION
This study has shown that plasma CgA is increased to abnormal
values in nearly 40% of patients with SCLC compared to healthy
individuals. Patients with a large tumour burden (ED) have signifi-
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Figure 1 Kaplan–Meier plot of the cumulative probability of survival for 150 patients with SCLC divided into two groups with normal and positive pretreatment
CgA-values. Compared by log-rank test*. P = 0.001
Overall survival
Years
02468
Normal CgA
Positive CgA
1.0
0.8
0.6
0.4
0.2
0.0
P = 0.03*
Figure 2 Kaplan–Meier plot of the cumulative probability of survival for 122 patients with SCLC living more than 30 days (no ‘early death’) divided into two
groups with normal and positive pretreatment CgA-values. Compared by log-rank test*. P = 0.03cantly higher values compared to patients with a smaller tumour
burden (LD). Survival is significantly worse for patients with
elevated CgA values and CgA is a significant prognostic factor –
also in multivariable analysis. To our knowledge, the only other
Cox analysis including CgA in SCLC is Johnson et al (1993).
Their model included NSE and albumin, and other cut-off levels
were used in LDH, PS, CgA and sodium. Their final Cox model
included NSE, PS and albumin, but this difference compared to
our model may be accidental considering that 101 patients in their
series, and 150 patients in our series, only enable identification of
few (three to four) influential factors.
The purpose of the study was to evaluate the clinical usefulness
of CgA as a prognostic factor and marker of disease activity – but
not as a tool for screening. Therefore a ‘reference group’ of only
28 healthy individuals was accepted and tested. For healthy adults,
the CgA values are not sex- or age-dependent (O’Connor and
Deftos, 1987; Hsaio et al, 1991). Our study has not been able to
confirm previous findings of elevated CgA in about 50% of
patients with LD and in about 70% of patients with ED (Sobol et
al, 1986; Johnson et al, 1993). Differences in analysis methods and
material (serum instead of plasma) are the most plausible reasons
for this. Chromogranin is probably a pro-hormone and several
degradation products are known (Helle and Angetti, 1994).
Precisely which is measured with the ELISA method needs clarifi-
cation, and variability from one ELISA test to another could be a
reason for lower values in this series.
Chromogranin A is a major constituent of catecholamine
storage vesicles and it is released with epinephrine and norepine-
phrine during exocytosis. One could therefore expect physio-
logical factors such as circadian cycle and stress to influence the
concentrations of CgA. All plasma samples were taken in the
morning before the patients got out of bed but not necessarily
fasting. However, eating does not influence CgA (Takiyyuddin 
et al, 1990). Another factor of influence is the kidney function
(Hsiao et al, 1990), but only one patient had a slightly increased
pretreatment creatinine; and the elevated CgA value in this patient
(3.67 nmol l–1) is best explained by extensive disease stage.
Several parameters have been analysed for prognostic value in
SCLC. The best described prognostic biochemical factor is LDH
(Østerlind et al, 1986; Buccheri and Ferrigno, 1994). However,
LDH is elevated in various malignant and non-malignant condi-
tions including inflammation. Even though increased plasma CgA
is not specific for SCLC, CgA is theoretically a much more
specific marker for SCLC, since CgA apart from brain and
adrenals only is present in tumour cells, whereas LDH is present in
the cytoplasm of all cells in the body. It is therefore meaningful
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Figure 3 Kaplan–Meier plot of the cumulative probability of survival for the three prognostic categories: good, intermediate and poor. Compared by log-rank
test: P < 0.00001that plasma-CgA provides additional prognostic value, as
confirmed in this investigation.
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